Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.
Bottom Line: The results showed that the serum MIC1 of ESCC was significantly higher than normal groups (P < 0.001), and was positively associated with tumor invasion (P = 0.030) as well as lymph node metastasis (P = 0.007).The antibody of MIC1 inhibited the tumor growth (P < 0.001), and showing preference for tumor tissues in xenograft model.The decreased formation of neovascularization lumen may be involved in the mechanism.
Affiliation: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Show MeSH
Related in: MedlinePlus
Mentions: Using the 250 normal samples as negative controls, the receiver operating characteristic (ROC) curve of MIC1, SCC, CA199, CEA and CA724 for ESCC is shown in Figure 2(a). The area under the ROC curve of the MIC1 is higher than that of SCC, CA199, CEA and CA724 (P < 0.001; Fig. 2a). The MIC1 threshold for diagnosis of esophageal cancer is set at 1000 pg/mL based on mean plus three standard deviations of healthy subjects, for the sake of usability in clinical settings. The sensitivity of MIC1 for diagnosis of ESCC was higher than that of SCC, CEA, CA199 and CA724 in a case of comparable specificity (Fig. 2a). Notably, the positive detection rate of MIC1 was 39.6% (19/48) in early-stage patients of ESCC (stages I), whereas only 6 of 48 early-stage patients were found to be positive for at least one of the other four markers suggesting that MIC1 may be used as a candidate marker for detecting early-stage ESCC.
Affiliation: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.